PEPG
PepGen Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.11
−2.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 1.7M | 1.4M | 1.5M | 1.2M | — |
| Gross Profit | (1.7M) | (1.4M) | (1.5M) | (1.2M) | — |
| Operating Expenses | |||||
| R&D Expense | 52.5M | 71.0M | 76.5M | 68.1M | 54.1M |
| SG&A Expense | 23.4M | 22.6M | 21.3M | 16.6M | 14.2M |
| General & Admin Expense | 23.4M | 22.6M | 21.3M | 16.6M | 14.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.4M) | (1.4M) | (1.5M) | (1.2M) | — |
| Total Operating Expenses | 74.5M | 92.2M | 96.2M | 83.6M | 68.3M |
| Cost and Expenses | 76.2M | 93.6M | 97.7M | 84.8M | 68.3M |
| Operating Income (EBIT) | (76.2M) | (93.6M) | (97.7M) | (84.8M) | (68.3M) |
| Non-Operating | |||||
| Interest Income | 4.4M | 4.0M | 7.1M | 6.4M | 2.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 4.4M | 4.0M | 7.1M | 6.4M | 2.8M |
| Other Non-Op Income/Expense | 4.4M | 4.0M | 7.1M | 6.2M | 2.9M |
| Non-Operating Income (excl Interest) | (2.3M) | (4.0M) | (7.1M) | (6.2M) | (2.9M) |
| EBT (Pre-Tax Income) | (71.9M) | (89.6M) | (90.6M) | (78.6M) | (65.4M) |
| Income Tax Expense | 65.0K | 49.0K | (617.0K) | 73.0K | 3.7M |
| Bottom Line | |||||
| Net Income | (71.9M) | (89.7M) | (90.0M) | (78.6M) | (69.1M) |
| Earnings from Cont. Ops | (71.9M) | (89.7M) | (90.0M) | (78.6M) | (69.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (71.9M) | (89.7M) | (90.0M) | (78.6M) | (69.1M) |
| Per Share | |||||
| Basic EPS | ($1.50) | ($2.12) | ($2.85) | ($3.30) | ($4.42) |
| Diluted EPS | ($1.50) | ($2.12) | ($2.85) | ($3.30) | ($4.42) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 69.2M | 42.2M | 31.6M | 23.8M | 15.6M |
| Diluted Shares Outstanding | 69.2M | 42.2M | 31.6M | 23.8M | 15.6M |
| Profitability Metrics | |||||
| EBITDA | (67.8M) | (88.2M) | (89.1M) | (77.4M) | (64.9M) |
| D&A | 6.1M | 1.4M | 1.5M | 1.2M | 493.0K |
| EBIT | (73.9M) | (89.6M) | (90.6M) | (78.6M) | (65.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026